Amneal Pharmaceuticals (NASDAQ:AMRX) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Amneal Pharmaceuticals (NASDAQ:AMRX) released its earnings results on Tuesday. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.03, FiscalAI reports. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%. The firm had revenue of $862.68 million for the quarter.

Here are the key takeaways from Amneal Pharmaceuticals’ conference call:

• Strong Q3 performance: Revenue rose 10% to $863 million, adjusted EBITDA increased 30% to $207 million, and adjusted EPS grew 53% to $0.26, prompting Amneal to raise its 2026 revenue, EBITDA, and EPS guidance.
• Affordable medicines revenue increased 19% to $547 million, supported by women’s health transdermal patches, new product launches, and biosimilar orders. The recently launched lanreotide generated approximately $7 million in late-September sales, with management expecting substantially higher revenue in Q4 and targeting 30%–40% market share.
• The completed Kashiv acquisition gives Amneal integrated biosimilar development, manufacturing, and commercialization capabilities. Management expects $400 million–$500 million of financial benefits over time and recently secured $60 million in New Jersey tax credits tied largely to biosimilar-related expansion.
• Specialty products continued to gain momentum, with CREXONT adding approximately 400 prescribers monthly and BREKIYA tracking ahead of expectations. Management expressed confidence that both products could reach the middle to high end of its long-term outlook.
• Operating cash flow guidance was reduced by $25 million at the midpoint to $325 million–$375 million because Amneal is building finished-goods inventory to meet demand and expects some collections to shift into Q1 2027. Net leverage was 3.0 times adjusted EBITDA after the Kashiv acquisition, with year-end leverage expected to rise to 3.6 times.

Amneal Pharmaceuticals Trading Down 0.6%

Amneal Pharmaceuticals stock traded down $0.12 during midday trading on Tuesday, reaching $20.32. The stock had a trading volume of 377,763 shares, compared to its average volume of 2,382,516. Amneal Pharmaceuticals has a twelve month low of $10.92 and a twelve month high of $21.68. The stock has a market capitalization of $6.49 billion, a PE ratio of 41.48, a price-to-earnings-growth ratio of 2.46 and a beta of 1.22. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The stock’s 50-day simple moving average is $19.17 and its 200 day simple moving average is $15.78.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Oppenheimer assumed coverage on shares of Amneal Pharmaceuticals in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $27.00 price objective for the company. The Goldman Sachs Group reissued a “buy” rating and issued a $24.00 target price on shares of Amneal Pharmaceuticals in a research report on Thursday. Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Finally, UBS Group reaffirmed a “buy” rating on shares of Amneal Pharmaceuticals in a research report on Thursday, October 1st. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.86.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, EVP Jason Daly sold 210,000 shares of the company’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the completion of the sale, the executive vice president directly owned 35,171 shares in the company, valued at $611,975.40. This represents a 85.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director John Kiely sold 50,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $17.64, for a total value of $882,000.00. Following the sale, the director owned 210,252 shares of the company’s stock, valued at $3,708,845.28. This represents a 19.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 413,016 shares of company stock valued at $7,216,567. Company insiders own 17.30% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.